A class of vaccines that consist of anti-idiotype monoclonal antibodies against the tumor-associated antigen disialoganglioside GD2 with potential antineoplastic activity. Vaccination with a monoclonal antibody GD2 anti-idiotype vaccine produces an immunoglobulin response against GD2 with subsequent destruction of GD2 positive tumor cells via antibody-dependent cellular cytotoxicity (ADCC). GD2 is overexpressed in melanoma, neuroblastoma, soft tissue sarcoma, and small cell carcinoma of the lung.
Leave a Comment
You must be logged in to post a comment.